{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:10:15Z","timestamp":1785499815084,"version":"3.56.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.ajog.2012.02.009","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T13:23:39Z","timestamp":1329830619000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Antidepressant use during pregnancy: the benefit-risk ratio"],"prefix":"10.1016","volume":"207","author":[{"given":"Gideon","family":"Koren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedvig","family":"Nordeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2012.02.009_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/bmj.323.7307.257","article-title":"Cohort study of depressed mood during pregnancy and after childbirth","volume":"323","author":"Evans","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2012.02.009_bib2","doi-asserted-by":"crossref","first-page":"544.e1","DOI":"10.1016\/j.ajog.2007.01.033","article-title":"Increasing use of antidepressants in pregnancy","volume":"196","author":"Cooper","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2012.02.009_bib3","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJM199804163381607","article-title":"Drugs in pregnancy","volume":"338","author":"Koren","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2012.02.009_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-199200432-00004","article-title":"Comparative efficacy of antidepressants","volume":"43","author":"Kasper","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.ajog.2012.02.009_bib5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/pds.1355","article-title":"Trends in antidepressant overdoses","volume":"16","author":"McKenzie","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajog.2012.02.009_bib6","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMc060602","article-title":"Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn","volume":"354","author":"Reefhuis","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2012.02.009_bib7","doi-asserted-by":"crossref","first-page":"194.e1","DOI":"10.1016\/j.ajog.2007.07.036","article-title":"Use of antidepressant medications during pregnancy: a multisite study","volume":"198","author":"Andrade","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2012.02.009_bib8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1056\/NEJM199701233360404","article-title":"Neurodevelopment of children exposed in utero to antidepressant drugs","volume":"336","author":"Nulman","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2012.02.009_bib9","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1001\/jama.1993.03500170076037","article-title":"Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac)","volume":"269","author":"Pastuszak","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2012.02.009_bib10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.279.8.609","article-title":"Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study","volume":"279","author":"Kulin","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2012.02.009_bib11","year":"2005"},{"key":"10.1016\/j.ajog.2012.02.009_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/698947","article-title":"Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat","author":"Diav-Citrin","year":"2012","journal-title":"Obstet Gynecol Int"},{"key":"10.1016\/j.ajog.2012.02.009_bib13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1176\/appi.ajp.2007.07060879","article-title":"Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy","volume":"165","author":"Einarson","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ajog.2012.02.009_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJMoa052744","article-title":"Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn","volume":"354","author":"Chambers","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2012.02.009_bib15","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1056\/NEJM199703203361211","article-title":"Birth outcomes in pregnant women taking fluoxetine","volume":"336","author":"Goldstein","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2012.02.009_bib16","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1471-0528.1998.tb10234.x","article-title":"The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England","volume":"105","author":"Wilton","year":"1998","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2012.02.009_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s002280050664","article-title":"Delivery outcome after the use of antidepressants in early pregnancy","volume":"55","author":"Ericson","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2012.02.009_bib18","first-page":"321","article-title":"Birth outcomes among pregnant women taking paroxetine (Paxil): OTIS 14th Annual Meeting Proceedings","volume":"63","author":"Unfred","year":"2001","journal-title":"Teratology"},{"key":"10.1016\/j.ajog.2012.02.009_bib19","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.AOG.0000187302.61812.53","article-title":"Risks associated with selective serotonin reuptake inhibitors in pregnancy","volume":"106","author":"Malm","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2012.02.009_bib20","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.ajog.2005.05.012","article-title":"Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome","volume":"193","author":"Sivojelezova","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2012.02.009_bib21","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.ede.0000239581.76793.ae","article-title":"Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations","volume":"17","author":"Wogelius","year":"2006","journal-title":"Epidemiology"},{"key":"10.1016\/j.ajog.2012.02.009_bib22","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ajog.2006.02.019","article-title":"Selective serotonin reuptake inhibitors and adverse pregnancy outcome","volume":"194","author":"Wen","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"suppl 1","key":"10.1016\/j.ajog.2012.02.009_bib23","first-page":"i12","article-title":"Congenital malformations after antidepressant medication with paroxetine in early pregnancy?","volume":"21","author":"Schloemp","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ajog.2012.02.009_bib24","doi-asserted-by":"crossref","first-page":"970","DOI":"10.2165\/00002018-200629100-00121","article-title":"Paroxetine and congenital malformations: a prospective comparative study","volume":"29","author":"Vial","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.ajog.2012.02.009_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.reprotox.2005.11.006","article-title":"Antidepressant drugs during pregnancy and infant congenital heart defects","volume":"21","author":"Kallen","year":"2006","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.ajog.2012.02.009_bib26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/bdra.20327","article-title":"Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations","volume":"79","author":"Kallen","year":"2007","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.ajog.2012.02.009_bib27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/pds.1462","article-title":"Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy","volume":"16","author":"Davis","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajog.2012.02.009_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/bdrb.20099","article-title":"First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage","volume":"80","author":"Berard","year":"2007","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.ajog.2012.02.009_bib29","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1056\/NEJMoa066584","article-title":"Use of selective serotonin-reuptake inhibitors in pregnancy and risk of birth defects","volume":"356","author":"Alwan","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2012.02.009_bib31","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/pds.1463","article-title":"Paroxetine in the first trimester and the prevalence of congenital malformations","volume":"16","author":"Cole","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajog.2012.02.009_bib32","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1056\/NEJMoa067407","article-title":"First-trimester use of selective serotonin-reuptake inhibitors and risk of birth defects","volume":"356","author":"Louik","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2012.02.009_bib33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2125.2008.03261.x","article-title":"Paroxetine and fluoxetine in pregnancy: a prospective multicentre, controlled, observational study","volume":"66","author":"Diav-Citrin","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2012.02.009_bib34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/bdrb.20144","article-title":"Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data","volume":"83","author":"Oberlander","year":"2008","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.ajog.2012.02.009_bib35","doi-asserted-by":"crossref","first-page":"b3569","DOI":"10.1136\/bmj.b3569","article-title":"Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study","volume":"339","author":"Pedersen","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2012.02.009_bib36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4065\/84.1.23","article-title":"Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy","volume":"84","author":"Wichman","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ajog.2012.02.009_bib37","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/bdra.20615","article-title":"Are selective serotonin reuptake inhibitors cardiac teratogens?","volume":"85","author":"Merlob","year":"2009","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.ajog.2012.02.009_bib38","first-page":"363","article-title":"The safety of escitalopram in pregnancy: a prospective cohort study","volume":"88","author":"Klieger-Grossmann","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.ajog.2012.02.009_bib39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CLEP.S9256","article-title":"Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis","volume":"2","author":"Kornum","year":"2010","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ajog.2012.02.009_bib40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/bdra.20641","article-title":"First trimester use of paroxetine and congenital heart defects: a population-based case-control study","volume":"88","author":"Bakker","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.ajog.2012.02.009_bib41","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1017\/S0033291709992194","article-title":"Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data","volume":"40","author":"Reis","year":"2010","journal-title":"Psychol Med"},{"key":"10.1016\/j.ajog.2012.02.009_bib42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.reprotox.2010.12.045","article-title":"Lack of teratogenic effect of citalopram\/escitalopram after in utero exposure","volume":"31","author":"Shechtman","year":"2011","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.ajog.2012.02.009_bib43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/AOG.0b013e318220edcc","article-title":"Selective serotonin reuptake inhibitors and risk for major congenital anomalies","volume":"118","author":"Malm","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2012.02.009_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/bdra.20627","article-title":"First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies","volume":"88","author":"Wurst","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.ajog.2012.02.009_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/bdra.20655","article-title":"Paroxetine exposure and during pregnancy and cardiac malformations","volume":"88","author":"Schialli","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.ajog.2012.02.009_bib46","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00228-011-1021-8","article-title":"Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records","volume":"67","author":"Kallen","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2012.02.009_bib47","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2012.02.009_bib48","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.clinthera.2007.05.003","article-title":"Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors","volume":"29","author":"Bar-Oz","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.ajog.2012.02.009_bib49","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.semperi.2008.08.001","article-title":"Fetal and neonatal effects of maternal drug treatment for depression","volume":"32","author":"Belik","year":"2008","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2012.02.009_bib50","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/pds.1570","article-title":"Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn","volume":"17","author":"Kallen","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajog.2012.02.009_bib51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-0030-1262507","article-title":"Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors","volume":"28","author":"Wilson","year":"2011","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2012.02.009_bib52","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1016\/j.prrv.2006.04.211","article-title":"Persistent pulmonary hypertension of the newborn","volume":"1","author":"Therese","year":"2006","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.ajog.2012.02.009_bib53","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S1701-2163(16)34157-3","article-title":"Diagnosis and management of poor neonatal adaptation syndrome in newborns exposed in utero to selective serotonin\/norepinephrine reuptake inhibitors","volume":"31","author":"Koren","year":"2009","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.ajog.2012.02.009_bib54","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/archpedi.156.11.1129","article-title":"Perinatal outcome following third trimester exposure to paroxetine","volume":"156","author":"Costei","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.ajog.2012.02.009_bib55","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/FTD.0b013e3181a58fb4","article-title":"Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations","volume":"31","author":"Boucher","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ajog.2012.02.009_bib56","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.ftd.0000187971.95000.25","article-title":"Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels","volume":"28","author":"Knoppert","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ajog.2012.02.009_bib57","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1176\/appi.ajp.159.11.1889","article-title":"Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study","volume":"159","author":"Nulman","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ajog.2012.02.009_bib58","unstructured":"Nulman I, Barrera M, Koren G, Feldman B. Unexposed siblings as controls for genetic confounders in studies on safety of psychotropic medications in pregnancy: novel methodology in behavioral teratology: session LBII-A-4. ASCPT Annual Meeting; Washington, DC: March 21, 2009."},{"key":"10.1016\/j.ajog.2012.02.009_bib59","series-title":"Medication safety in pregnancy and breastfeeding","first-page":"5","article-title":"Gestational changes in drug disposition in the maternal-fetal unit","author":"Gedeon","year":"2007"},{"key":"10.1016\/j.ajog.2012.02.009_bib60","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1517\/14740338.2011.583917","article-title":"Antidepressant use in pregnancy","volume":"10","author":"Lorenzo","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ajog.2012.02.009_bib61","first-page":"489","article-title":"Discontinuing antidepressants and benzodiazepines upon becoming pregnant","volume":"47","author":"Einarson","year":"2001","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.ajog.2012.02.009_bib62","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.295.5.499","article-title":"Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment","volume":"295","author":"Cohen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2012.02.009_bib63","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1192\/bjp.150.6.782","article-title":"Detection of postnatal depression: development of the 10-item Edinburgh Postnatal Depression Scale","volume":"150","author":"Cox","year":"1987","journal-title":"J Psychiatry"},{"key":"10.1016\/j.ajog.2012.02.009_bib64","first-page":"777","article-title":"Screening for depressive symptoms","volume":"57","author":"Walfisch","year":"2011","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.ajog.2012.02.009_bib65","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/0002-9378(89)90186-5","article-title":"Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester","volume":"160","author":"Koren","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2012.02.009_bib66","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/tera.1420410602","article-title":"Prevention of unnecessary pregnancy terminations by counseling women on drug, chemical, and radiation exposure during the first trimester","volume":"41","author":"Koren","year":"1990","journal-title":"Teratology"},{"key":"10.1016\/j.ajog.2012.02.009_bib67","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00737-005-0094-8","article-title":"Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making","volume":"8","author":"Bonari","year":"2005","journal-title":"Arch Women Ment Health"},{"key":"10.1016\/j.ajog.2012.02.009_bib68","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/uog.2716","article-title":"Isolated ventricular septal defects detected by color Doppler imaging: evolution during fetal and first year of postnatal life","volume":"27","author":"Axt-Fliedner","year":"2006","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2012.02.009_bib70","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PSY.0b013e31803cb862","article-title":"Anxiety, depression, and cause-specific mortality: the Hunt study","volume":"69","author":"Mykletun","year":"2007","journal-title":"Psychosomatic Med"},{"key":"10.1016\/j.ajog.2012.02.009_bib71","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4088\/JCP.10m06135","article-title":"A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure","volume":"72","author":"Suri","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.ajog.2012.02.009_bib72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2125.1994.tb04331.x","article-title":"A novel index for expressing exposure of the infant to drugs in breast milk","volume":"38","author":"Ito","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2012.02.009_bib74","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0002-9378(03)00868-8","article-title":"Frequency of infant adverse events that are associated with citalopram use during breast-feeding","volume":"190","author":"Lee","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2012.02.009_bib75","first-page":"1030","article-title":"Transfer of drugs and other chemicals into human milk","volume":"110","year":"2002","journal-title":"Pediatrics"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937812001561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937812001561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T10:45:20Z","timestamp":1757587520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937812001561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0002937812001561"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2012.02.009","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidepressant use during pregnancy: the benefit-risk ratio","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2012.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}